Fuh, K., Moore, K., Baert, T., Herzog, T., Cibula, D., Liu, J., … Gonzalez-Martin, A. (2022). TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66). In International Journal of Gynecological Cancer (Vol. 32, pp. A234–A235). Elsevier BV. https://doi.org/10.1136/ijgc-2022-igcs.532

Fuh, Katherine, Kathleen Moore, Thais Baert, Thomas Herzog, David Cibula, Joyce Liu, Laurianne Eberst, et al. “TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66).” In International Journal of Gynecological Cancer, 32:A234–35. Elsevier BV, 2022. https://doi.org/10.1136/ijgc-2022-igcs.532.

Fuh K, Moore K, Baert T, Herzog T, Cibula D, Liu J, et al. TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66). In: International Journal of Gynecological Cancer. Elsevier BV; 2022. p. A234–5.

Fuh, Katherine, et al. “TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66).” International Journal of Gynecological Cancer, vol. 32, Elsevier BV, 2022, pp. A234–35. Crossref, doi:10.1136/ijgc-2022-igcs.532.

Fuh K, Moore K, Baert T, Herzog T, Cibula D, Liu J, Eberst L, Lewin S, Secord AA, Sehouli J, Myers T, Bamias A, Rimel BJ, Colombo N, Franke AMY, Shoop D, De Giorgi UGO, Pikiel J, Bowen R, Gonzalez-Martin A. TP023/#1560 A phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept in combination with weekly paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66). International Journal of Gynecological Cancer. Elsevier BV; 2022. p. A234–A235.